Genetic engineering concept. Medical science. Scientific Laboratory.
image-

Positive Preclinical Data for LinearDNA™ as Novel Cancer Vaccine Strategy

Posted on

STONY BROOK, N.Y. and ROME, ITALY – June 6, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. (“EvviVax”), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform […]

Read More email

image-

Beefing Up Cancer Treatments, With A Vaccine In Sight

Posted on

Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]

Read More email

image-

Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Posted on

– First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen – – Targeted Vaccines Elicit a Therapeutic Immune Response in Animal Cancer Models – – LinearDNA Vaccines Elicits Strong Antigen-specific Immune Responses and Significantly Reduces Tumor Growth – – Manuscript Summarizing Findings Posted to Preprint Server and Submitted for Peer-Reviewed Publication – STONY BROOK, […]

Read More email

image-

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

Posted on

STONY BROOK, N.Y. and ROME, ITALY – June 7, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated […]

Read More email

image-

Applied DNA, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Posted on

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines Manufactured by an enzyme and without bacteria, LinearDNA vaccine candidate is virus-free, plasmid-free DNA Vaccine candidate induced neutralizing titers in 100% of trial cohort Based on positive study results, companies plan to accelerate […]

Read More email

image-

Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Felines

Posted on

– COVID Feline Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models – – Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines –STONY BROOK, N.Y. & ROME. March 2, 2021. Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), […]

Read More email

image-

Applied DNA Develops Linear DNA Veterinary COVID-19 Vaccine

Posted on

Applied DNA Achieves Program Milestone in Development of  Linear DNA Veterinary COVID-19 Vaccine – Qualifies Freeze-Dried Version of LinearDNA™ COVID-19 Vaccine Candidate Ahead of Initiation of Feline Clinical Trial – –  Reconstituted Vaccine Candidate Demonstrates Potency, Validating Easy Shipment in Dry State – – Feline Clinical Trial On-Track to Begin by March 31, 2021 – […]

Read More email

image-

Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate

Posted on

Trial Redesigned to Accelerate Development of Clinical Path to Potential USDA APHIS Conditional License for Commercial Veterinary Sales STONY BROOK, N.Y. – November 30, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotech with expertise […]

Read More email

image-

APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

Posted on

STONY BROOK, N.Y. – September 16, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, preclinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it and Evvivax, S.R.L., a spin-out of Takis Biotech […]

Read More email

image-

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Posted on

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse […]

Read More email

image-

Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

Posted on

STONY BROOK, N.Y., March 1, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement (“JDA”) entered […]

Read More email

image-

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

Posted on

Published: Sep 20, 2018 By Mark TerryLineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines. Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will use […]

Read More email

image-

Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

Posted on

STONY BROOK N.Y., September 20, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”), biotechnology companies focused on the discovery and development of […]

Read More email